![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4674c273-ee8e-4d09-9468-d333c7522490/gr1.gif)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet
![Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0049bf76-c153-4c19-b434-4f0e53df4489/gr1.jpg)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology
![Lung Cancer Patient Still Going Strong a Year After Diagnosis Thanks to New Immunotherapy | Jefferson Health New Jersey Lung Cancer Patient Still Going Strong a Year After Diagnosis Thanks to New Immunotherapy | Jefferson Health New Jersey](https://newjersey.jeffersonhealth.org/sites/default/files/Nancy%20Knighton%20%26%20Docs%20small.jpg)
Lung Cancer Patient Still Going Strong a Year After Diagnosis Thanks to New Immunotherapy | Jefferson Health New Jersey
![First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health](https://www.englewoodhealth.org/wp-content/uploads/2018/08/spotlight_calypso.jpg)
First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health
![New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/sites/default/files/styles/large/public/node/234817/3x2/adusumilli-prasad_210914_010-1200x800.jpg)
New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy | Memorial Sloan Kettering Cancer Center
![24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8909c5a9-ab2e-4cb0-9e07-6d3dab4314fb/gr1_lrg.jpg)